Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetVivo Holdings, Inc. (PETV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with Commission File Number 001-40715, PetVivo submits current reports, periodic reports and exhibits that document material events, governance changes, financing transactions and investor communications related to its animal health and veterinary AI businesses.
For PetVivo, Form 8-K current reports are particularly relevant. Recent 8-K filings have covered topics such as the appointment and resignation of directors, changes in board size, entry into note conversion agreements with shareholders, and the furnishing of investor presentations under Regulation FD. These filings can give investors insight into PetVivo’s corporate governance, capital structure adjustments and how it communicates its strategy around products like SPRYNG with OsteoCushion technology, PrecisePRP and the PetVivo.ai platform.
In addition to current reports, investors may consult PetVivo’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for detailed information on business operations, risk factors, financial statements and segment discussions related to its veterinary medical devices, regenerative products and AI initiatives. Form 4 and other ownership filings, when filed, can be used to monitor equity transactions by directors, officers and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping readers interpret complex disclosures such as note conversions, licensing agreements or board changes. Real-time updates from EDGAR ensure that new PETV filings appear promptly, while structured access to exhibits like investor presentations allows users to review the same materials referenced in PetVivo’s Regulation FD communications.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.